BIO Calls for New Approval Process for Rare Disease Drugs

BIO Calls for New Approval Process for Rare Disease Drugs
WASHINGTON – Although lawmakers have proposed increasing by million the appropriations for the grants program administered by the FDA’s Office of Orphan Products Development (OOPD), more incentives are needed to spur innovation and development for rare and genetic disease medicines, Amicus Therapeutics CEO John Crowley told a Senate committee last week.
Read more on BioWorld